Navigation Links
Transition Therapeutics Announces Milestone Payment from Elan
Date:12/24/2007

TORONTO, Dec. 24 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), announced today that the Company will receive a US$5million milestone payment under its global collaboration agreement with a subsidiary of Elan Corporation, plc ("Elan") (NYSE: ELN). The milestone payment was triggered by the initiation of a Phase 2 clinical study of Alzheimer's disease drug candidate, ELND005 (AZD-103), which was jointly announced by Transition and Elan on December 21, 2007.

In connection with the enrolment of the first patient in the Phase 2 clinical study, Transition will issue the former shareholders of Ellipsis Neurotherapeutics Inc. ("ENI") 174,123 Transition common shares at a price of $10.86 per share, which represents the weighted average trading price for the last five trading days. The financial terms associated with the acquisition of ENI were previously disclosed in a press release dated March 13, 2006.

About Transition

----------------

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally or developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit http://www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.


'/>"/>
SOURCE Transition Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
2. Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc
3. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2008 Financial Results on Wednesday, November 14, at 8:30 A.M. EST
4. New UIC center to study end-of-life transition
5. Seabrook House Opens Transitional Living Facility: Seabrook West
6. Prime Therapeutics Receives TIPPS Certification
7. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
8. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
9. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
10. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
11. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , ... May 31, 2016 , ... Phynd Technologies, Inc. ... GA; Houston Methodist – Houston, TX and Shore Medical Center – Somers Point, NJ. ... three different, leading EHR solutions, demonstrating the breadth of Phynd’s solution and its interoperability. ...
(Date:5/31/2016)... ... , ... In a recent interview on The Greenburgh Report radio show hosted ... WVOX (1460 AM), leading medical insurance advocate Adria Goldman Gross discussed several eye-opening ... maelstrom.” , During the interview with Mr. Feiner that aired on May 7, ...
(Date:5/31/2016)... ... ... Dr. Charles A. Ditta attained his Doctor of Medical Dentistry Degree from ... where he graduated in the top ten percentile of his class. Dr. Ditta has ... has been a member in good standing for thirty years in the American Dental ...
(Date:5/31/2016)... ... May 31, 2016 , ... To meet ... to the healthcare industry, The University of Scranton is adding a Certificate in ... to a career in rapidly growing field of healthcare information. , Healthcare ...
(Date:5/31/2016)... ... May 31, 2016 , ... Super Powder, a supplement produced ... the go individuals and dedicated athletes, continues to transform the nutritional supplement industry by ... pea and milk protein, branched-chain amino acids (BCAA), alkaline minerals, wheat grass, digestive enzymes, ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... , May 30, 2016 ... titled, "Advanced (3D/4D) Visualization Systems Market - Global Industry ... 2024." According to the report, the global advanced (3D/4D) ... in 2015 and is anticipated to expand at a ... US$ 3.2 Bn in 2024. Advanced (3D/4D) ...
(Date:5/30/2016)... -- - DCGI grants limited approval to market Stempeucel® ... - Stempeucel® becomes 5th off-the-shelf Stem cell product to be ... - Buerger,s Disease (also known as Thromboangiitis Obliterans) is a major ... - Prevalence of Buerger,s Disease is estimated to be ... persons in the European Community & USA ...
(Date:5/27/2016)... PUNE, India , May 27, 2016 ... in the instances of hypertension is driving ambulatory blood ... muscles lose their elasticity and their ability to respond ... blood pressure. This condition can lead to various cardiovascular ... and peripheral vascular disease. These diseases are growing in ...
Breaking Medicine Technology: